131.25MMarket Cap2.76P/E (TTM)
1.975High1.800Low1.80MVolume1.820Open1.810Pre Close3.47MTurnover3.50%Turnover Ratio2.76P/E (Static)68.01MShares30.50052wk High0.30P/B99.43MFloat Cap1.70052wk Low--Dividend TTM51.52MShs Float41.930Historical High--Div YieldTTM9.67%Amplitude1.700Historical Low1.923Avg Price1Lot Size
Amylyx Pharmaceuticals Stock Forum
Update
Benzinga· 4 mins ago
Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression
- All eight participants met prespecified r...
NEWS
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced positive interim data from the Phase 2 HELIOS clinical trial of AMX0035 in adults with Wolfram syndrome. The data showed improvements in pancreatic function, glycemic control, and vision, with all parti...
But some good now! Hehehe
A bit more
Update! Hmm? Grrr!
Moomoo 24/7· 1 min ago
Relyvrio/Albrioza will no longer be available for new patients as of today; Patients currently on therapy in the U.S. and Canada who, in consultation with their physician, wish to continue can be transitioned to a free drug program; PHOENIX Open Label Extension is ongoing
one at 15!
so many share traded at 3.34 no record in data but you can see it when market open that time in trades. I belive more than 500k shares crazy
No comment yet